Since the very beginning of the COVID-19 pandemic, in addition to the attempts to rapidly develop a vaccine that was effective against current strains, researchers have been looking for a vaccine that could protect more broadly against multiple coronaviruses. That has prompted attempts to harness the potential of the more conserved S2 subunit of the spike protein via which SARS-CoV-2 enters human host cells.